| Description | D-Lin-MC3-DMA, an ionizable cationic lipid, is a potent siRNA delivery vehicle. |
| In vitro | 将DSPC替换为不饱和PCs，并将DLin-MC3-DMA替换为相关脂质DLin-KC2-DMA，可显著提高HeLa细胞体外转染试剂的效能。 |
| Cell experiments | White leghorn chicken embryos at stage 24 (30) were removed and dissected in Hanks buffered saline solution (HBSS).?Forelimbs were pooled and treated for 1 h in dispase to remove epithelial ectoderm.?Limb mesenchyme was dissociated, and resuspended in DMEM with 5% FBS and 1% penicillin/streptomycin.?Cells were plated onto 96-well plates at a density of 2x10^5 or 2x10^7 cells/ml and treated with 0-40 μg/ml LNP-pDNA.?Cultures were incubated overnight at 37℃ and resuspended in PBS buffer for expression analysis using a BD LSRII flow cytometer.?Cell survival was assessed in low-density cultures after 24 h of treatment, by counting the adherent cells remaining after PBS washes.?Viability was determined based on average counts of all adherent cells within a single field of view (100x) normalized to cell counts of untreated cultures. |
| molecular weight | 642.09 |
| Molecular formula | C43H79NO2 |
| CAS | 1224606-06-7 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | Ethanol: 16.67 mg/mL (25.96 mM) DMSO: 43.33 mg/mL (67.48 mM) |
| References | 1. Kulkarni J A , Myhre J L , Chen S , et al. Design of lipid nanoparticles for, in vitro, and, in vivo, delivery of plasmid DNA[J]. Nanomedicine: Nanotechnology, Biology and Medicine, 2017, 13(4):1377-1387. |
| Citations | 1. Morales L C, Rajendran A, Ansari A, et al.Biodistribution of Therapeutic Small Interfering RNAs Delivered with Lipid-Substituted Polyethylenimine-Based Delivery Systems.Molecular Pharmaceutics.2024 2. Marcos-Villar L, Perdiguero B, Anthiya S, et al.Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium.npj Vaccines.2024, 9(1): 53. 3. Marcos-Villar L, Perdiguero B, López-Bravo M, et al.Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.Emerging Microbes & Infections.2024 (just-accepted): 2387906. |